Clinical trial · Observational
Myeloid-derived Suppressor Cells in Colorectal Cancer
Myeloid-derived Suppressor Cells in Colorectal Cancer: Influence on Postoperative Complications and Neoadjuvant Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate whether the preoperative level of myeloid-derived suppressor cells is associated with postoperative complications classified by Clavien-Dindo categories. Levels of all MDSC, polymorphonuclear MDSC (PMNMDSC), monocytic MDSC (MMDSC), early-stage MDSC (EMDSC) and monocytic to polymorphonuclear MDSC ratio (M/PMN MDCS) were established and compared in patients with postoperative complications, severe postoperative complications (\>= IIIA according to Clavien-Dindo) and severe septic complications.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Complication,Postoperative | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
| Suppression | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Level of Myeloid-Derived Suppressor Cells | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Colorectal cancer
- description
- Patients with colorectal cancer qualified for elective operations.
- interventionNames
- Diagnostic Test: Level of Myeloid-Derived Suppressor Cells
Primary outcomes (1)
- measure
- Level of MDSC in patients with postoperative complications
- timeFrame
- 30 days
- description
- Level of all MDSC, polymorphonuclear MDSC (PNMMDSC), monocytic MDSC ( MMDSC), early-stage MDSC (EMDSC) and monocytic to polymorphonuclear MDSC ratio (M/PMNMDSC) in patients with postoperative complications
Secondary outcomes (6)
- measure
- Level of MDSC in patients with severe postoperative complications
- timeFrame
- 30 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age ≥ 18 * colorectal cancer confirmed by histological examination of biopsy specimen * elective operation * signed informed consent Exclusion Criteria: * Age \< 18 * Pregnancy or lactation * Emergency operation * General condition that precludes understanding and signing of the informed consent form
References
Publications (1)
- RESULTRogala J, Sieminska I, Baran J, Rubinkiewicz M, Zybaczynska J, Szczepanik AM, Pach R. Myeloid-Derived Suppressor Cells May Predict the Occurrence of Postoperative Complications in Colorectal Cancer Patients-a Pilot Study. J Gastrointest Surg. 2022 Nov;26(11):2354-2357. doi: 10.1007/s11605-022-05364-3. Epub 2022 Jun 1. No abstract available. PMID 35650461